| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Equillium Inc. | Itolizumab - (EQUATOR) | 1st line Acute graft-versus-host disease (aGVHD) | Phase 3 | Trial Completed | Intravenous | Immunosuppressant |
| Equillium Inc. | Itolizumab | Ulcerative colitis (UC) | Phase 2 | Data Released | Intravenous | Gastroenterology |
| Equillium Inc. | EQ101 | Alopecia areata | Phase 2 | Trial Planned | oral | Immunology |
| Equillium Inc. | Itolizumab (EQ001) | COVID-19 | Phase 3 | Trial Discontinued | Intravenous | COVID-19 |
| Equillium Inc. | Itolizumab (EQ001) - (EQUATE) | Acute graft-versus-host disease | Phase 3 | Ongoing | Intravenous | Immunosuppressant |
| Equillium Inc. | Itolizumab (EQ001) | COVID-19 | Phase 3 | Trial Discontinued | Intravenous | COVID-19 |
| Equillium Inc. | Itolizumab - (EQUATOR) | 1st line Acute graft-versus-host disease (aGVHD) | Phase 3 | Trial Completed | Intravenous | Immunosuppressant |
| Erasca Inc. | Naporafenib plus trametinib (SEACRAFT-2) | NRASm melanoma | Phase 3 | Ongoing | Oral | Oncology |